Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Kissei: Pharm. Sales Down 0.5%, Profits Up
November 7, 2011
- ASKA: Sales Down 8.4% Due to Rebound from a Spike at Last Fiscal Year End
November 7, 2011
- Breast Cancer Project Selected for Health Science Research Grant: 3-D Matrix
November 7, 2011
- Pharmacies Satisfied, Wholesalers Dissatisfied with Price Negotiations: Yano Research Survey
November 7, 2011
- CMIC: Sales, Profits Up Driven by CRO Business
November 7, 2011
- Kawasumi Lab.: Declines in Sales, Profits
November 7, 2011
- Takara Bio: Research Reagents Drive Growth in Sales, Profits
November 7, 2011
- Sales of Actos Down 22% in 1st Half Due to Bladder Cancer Concerns, Generic Competition: Takeda
November 5, 2011
- Qol Decides to Discontinue “Dispensing Points” in March 2012
November 4, 2011
- Ono President Says Glactiv to “Still Show Advantage of Early Release”
November 4, 2011
- Asahi Kasei Pharma’s Apr-Sep Sales Up 6% Due to Doubled Recomodulin Sales
November 4, 2011
- Once-Yearly Dosing Osteoporosis Agent Starts PIII Study: Asahi Kasei Pharma
November 4, 2011
- FDA Assigns Action Date of Jan 25, 2012 for Takeda’s Alogliptin
November 4, 2011
- Sales of Medical & Pharmaceutical Business Increased 2.4% Driven by New Drugs: Teijin
November 4, 2011
- Astellas: Sales, Profits Up in First Half Driven by Vesicare
November 4, 2011
- Eisai Announces Double-digit Declines in 1st-Half Sales, Profits
November 4, 2011
- Kaken: Mainstay Products, Generics Pull Business
November 4, 2011
- Santen Sends Expert Researchers to US, Europe to Assess Candidate Compounds for In-licensing
November 4, 2011
- Anti-androgen Drug MDV3100 Significantly Improves OS in PIII AFFIRM Trial: Astellas
November 4, 2011
- Complaints of Side Effects from Lyrica Up Sharply: Nextit Research
November 4, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…